SCHEMBL4099593

SCHEMBL4099593

CC(=O)N1CCN(c2nc(-c3ccccc3F)nc3cccc(F)c23)CC1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HIF1A Q16665 1/20 0.51
MAPT P10636 4/20 0.51
GBA1 P04062 1/20 0.49
LMNA P02545 1/20 0.48
MEN1 O00255 3/20 0.45
KMT2A Q03164 3/20 0.45
KDM4E B2RXH2 2/20 0.45
TP53 P04637 1/20 0.45
THRB P10828 1/20 0.45
PKM P14618 1/20 0.45
CASP1 P29466 1/20 0.45
KLK7 P49862 1/20 0.45
CASP7 P55210 1/20 0.45
PIK3CD O00329 1/20 0.44
NCF1 P14598 2/20 0.42
ALDH1A1 P00352 2/20 0.41
HTT P42858 2/20 0.41
SMN1; SMN2 Q16637 2/20 0.41
SMO Q99835 1/20 0.40
CNR2 P34972 2/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4095765 0.91 MAPT (0.53) HIF1AMAPTGBA1LMNAMEN1
SCHEMBL4095229 0.91 CNR2 (0.48) HIF1AMAPTGBA1LMNAMEN1
SCHEMBL4090816 0.87 HIF1A (0.68) HIF1AMAPTGBA1LMNAMEN1
SCHEMBL4090732 0.86 KMT2A (0.53) HIF1AMAPTLMNAMEN1KMT2A
SCHEMBL4091224 0.83 HIF1A (0.71) HIF1AMAPTGBA1LMNAMEN1
SCHEMBL4090729 0.82 ABCB1 (0.52) MAPTGBA1MEN1KMT2AKDM4E
SCHEMBL4095191 0.80 MAPT (0.62) HIF1AMAPTGBA1LMNAMEN1
SCHEMBL4085062 0.79 CNR2 (0.49) MAPTGBA1LMNAMEN1KMT2A
SCHEMBL4099740 0.79 KMT2A (0.50) HIF1AMAPTLMNAMEN1KMT2A
SCHEMBL4094778 0.79 KMT2A (0.50) MAPTLMNAMEN1KMT2AKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090209536-A1 AMINOQUINAZOLINE CANNABINOID RECEPTOR MODULATORS FOR TREATMENT OF DISEASE KALYPSYS, INC. (US) 2009-08-20 US disclosed
US-20090209536-A1 AMINOQUINAZOLINE CANNABINOID RECEPTOR MODULATORS FOR TREATMENT OF DISEASE KALYPSYS, INC. (US) 2009-08-20 US disclosed
US-20090209536-A1 AMINOQUINAZOLINE CANNABINOID RECEPTOR MODULATORS FOR TREATMENT OF DISEASE KALYPSYS, INC. (US) 2009-08-20 US disclosed
WO-2008157500-A1 AMINOQUINAZOLINE CANNABINOID RECEPTOR MODULATORS FOR TREATMENT OF DISEASE KALYPSYS, INC. (US) 2008-12-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090209536-A1 AMINOQUINAZOLINE CANNABINOID RECEPTOR MODULATORS FOR TREATMENT OF DISEASE CNR2, CNR1, GPR18 HIF1A 1496/4885MAPT 4125/4885GBA1 2059/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.